Repair blend
A fixed-ratio combination of GHK-Cu, BPC-157, and TB-500 covering the three stages of tissue repair.
GLOW is not a proprietary molecule; it is three well-characterized peptides in one vial at a fixed ratio. The name comes from its components. What makes it coherent rather than arbitrary is that the three address different stages of the same process: getting cells to the site of damage, building the blood supply and repairing the tissue, and laying down the structural protein that holds the result together.
Think of repair as three jobs. TB-500 mobilizes cells and gets them to where the damage is. BPC-157 builds the blood supply that makes repair possible and drives the repair itself. GHK-Cu lays down collagen and elastin — the structural result. All three independently increase VEGF and reduce inflammatory signaling, which is why they stack coherently instead of just occupying the same vial.
TB-500 sequesters G-actin via the LKKTET motif, regulating cytoskeletal reorganization for cell migration. BPC-157 upregulates VEGF and modulates nitric oxide signaling, driving angiogenesis while reducing TNF-α and IL-6, and enhances fibroblast migration and collagen organization. GHK-Cu modulates expression across thousands of genes, upregulating collagen I and III, elastin, and glycosaminoglycans while downregulating MMPs and inflammatory cytokines. Convergence on VEGF and fibroblast activation is the basis of the combination rationale.
The components operate on different timelines. Anti-inflammatory effects come first, cellular migration within days, and collagen-mediated changes — the visible ones — over weeks. Skin and hair outcomes in the GHK-Cu literature are typically assessed at eight to twelve weeks, which is a reasonable expectation to carry into this.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
Component-level tolerability is generally favorable, but none of the three is FDA- or EMA-approved and the combination has not been formally studied. Copper-containing compounds warrant caution in anyone with a copper metabolism disorder such as Wilson's disease. The angiogenic mechanism — growing new blood vessels — is the reason anyone with an active or historical malignancy should discuss this with their oncologist rather than proceeding independently. Not appropriate during pregnancy or breastfeeding.
Blends compound the sourcing problem: you are now trusting three synthesis processes and the accuracy of the ratio. Insist on a certificate of analysis that reports the blend as manufactured, not three separate documents for the ingredients.
KLOW is GLOW plus KPV. That addition brings a dedicated anti-inflammatory mechanism, making KLOW the more appropriate choice when inflammation is the limiting factor. GLOW rebuilds; KLOW calms first, then rebuilds.
Not inherently. A blend is more convenient and enforces a ratio someone else chose. Separate vials cost more effort and allow you to adjust one component without changing the others.
No. The evidence is component-level. The combination rationale is mechanistic.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation